Given that serum levels of the proinflammatory cytokine IL-6 are significantly elevated in patients with severe COVID-19, clinical trials have been initiated to evaluate antibodies that block IL-6 or IL-6 receptor such as tocilizumab (Actemra, Roche; currently in 35 Clinical Trials, e.g., NCT04317092) and sarilumab (Kevzara, Regeneron; currently in 12 Clinical Trials, e.g., NCT04315298). This evidence concerns the gene IL6 and COVID-19.